SG11201507255QA - Tricyclic compounds as inhibitors of immunosuppression mediated by tryptophan metabolization - Google Patents

Tricyclic compounds as inhibitors of immunosuppression mediated by tryptophan metabolization

Info

Publication number
SG11201507255QA
SG11201507255QA SG11201507255QA SG11201507255QA SG11201507255QA SG 11201507255Q A SG11201507255Q A SG 11201507255QA SG 11201507255Q A SG11201507255Q A SG 11201507255QA SG 11201507255Q A SG11201507255Q A SG 11201507255QA SG 11201507255Q A SG11201507255Q A SG 11201507255QA
Authority
SG
Singapore
Prior art keywords
metabolization
tryptophan
inhibitors
tricyclic compounds
immunosuppression mediated
Prior art date
Application number
SG11201507255QA
Inventor
Sanjeev Kumar
Jesse Waldo
Firoz Jaipuri
Mario Mautino
Original Assignee
Newlink Genetics Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50686105&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11201507255Q(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Newlink Genetics Corp filed Critical Newlink Genetics Corp
Publication of SG11201507255QA publication Critical patent/SG11201507255QA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
SG11201507255QA 2013-03-14 2014-03-10 Tricyclic compounds as inhibitors of immunosuppression mediated by tryptophan metabolization SG11201507255QA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361784089P 2013-03-14 2013-03-14
PCT/US2014/022680 WO2014159248A1 (en) 2013-03-14 2014-03-10 Tricyclic compounds as inhibitors of immunosuppression mediated by tryptophan metabolization

Publications (1)

Publication Number Publication Date
SG11201507255QA true SG11201507255QA (en) 2015-10-29

Family

ID=50686105

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201707545XA SG10201707545XA (en) 2013-03-14 2014-03-10 Tricyclic compounds as inhibitors of immunosuppression mediated by tryptophan metabolization
SG11201507255QA SG11201507255QA (en) 2013-03-14 2014-03-10 Tricyclic compounds as inhibitors of immunosuppression mediated by tryptophan metabolization

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG10201707545XA SG10201707545XA (en) 2013-03-14 2014-03-10 Tricyclic compounds as inhibitors of immunosuppression mediated by tryptophan metabolization

Country Status (22)

Country Link
US (2) US9617272B2 (en)
EP (2) EP2976332B1 (en)
JP (2) JP6093903B2 (en)
KR (1) KR20150126623A (en)
CN (1) CN105189466A (en)
AU (2) AU2014241079C1 (en)
BR (1) BR112015022588A2 (en)
CA (1) CA2902174A1 (en)
CL (2) CL2015002649A1 (en)
CR (1) CR20150485A (en)
HK (1) HK1213259A1 (en)
IL (1) IL241027A0 (en)
MA (1) MA38493B1 (en)
MX (1) MX361375B (en)
PE (1) PE20151593A1 (en)
PH (1) PH12015501866A1 (en)
RU (1) RU2667509C2 (en)
SA (1) SA515361127B1 (en)
SG (2) SG10201707545XA (en)
UA (1) UA118103C2 (en)
WO (1) WO2014159248A1 (en)
ZA (1) ZA201607948B (en)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO2694640T3 (en) 2011-04-15 2018-03-17
US9604982B2 (en) 2013-03-14 2017-03-28 Janssen Pharmaceutica Nv P2X7 modulators
JO3773B1 (en) 2013-03-14 2021-01-31 Janssen Pharmaceutica Nv P2x7 modulators
ES2689526T3 (en) 2013-03-14 2018-11-14 Janssen Pharmaceutica Nv P2X7 modulators
TWI627174B (en) 2013-03-14 2018-06-21 比利時商健生藥品公司 P2x7 modulators
SG11201507382QA (en) 2013-03-14 2015-10-29 Boehringer Ingelheim Int Substituted 2-aza-bicyclo[2.2.1]heptane-3-carboxylic acid (benzyl-cyano-methyl)-amides inhibitors of cathepsin c
CN103570727B (en) 2013-11-12 2015-08-19 复旦大学 A kind of N-benzyl couroupitine A derivative and its preparation method and application
US9771370B2 (en) * 2014-09-05 2017-09-26 Merck Patent Gmbh Compounds for the inhibition of indoleamine-2,3-dioxygenase
JP2017526716A (en) 2014-09-12 2017-09-14 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Spirocyclic inhibitors of cathepsin C
US10150766B2 (en) 2014-09-12 2018-12-11 Janssen Pharmaceutica Nv P2X7 modulators
GB201417369D0 (en) * 2014-10-01 2014-11-12 Redx Pharma Ltd Compounds
US20160145344A1 (en) * 2014-10-20 2016-05-26 University Of Southern California Murine and human innate lymphoid cells and lung inflammation
CA2965741C (en) * 2014-11-03 2022-05-17 Iomet Pharma Ltd Pharmaceutical compound
US10525035B2 (en) 2014-12-18 2020-01-07 Lankenau Institute For Medical Research Methods and compositions for the treatment of retinopathy and other ocular diseases
CN105884828A (en) * 2015-02-16 2016-08-24 上海迪诺医药科技有限公司 Polycyclic compound, pharmaceutical composition and application thereof
CN107531693B (en) * 2015-04-10 2021-07-06 百济神州有限公司 5 or 8-substituted imidazo [1, 5-a ] pyridines as indoleamine, tryptophan dioxygenase inhibitors
WO2016165613A1 (en) 2015-04-12 2016-10-20 Hangzhou Innogate Pharma Co., Ltd. Heterocycles useful as ido and tdo inhibitors
CA2985642A1 (en) * 2015-05-15 2016-11-24 Gilead Sciences, Inc. Benzimidazole and imadazopyridine carboximidamide compounds having activity as inhibitors of indoleamine 2,3-dioxygenase
GB2548542A (en) * 2015-06-16 2017-09-27 Redx Pharma Plc Compounds
CN105037371A (en) * 2015-06-30 2015-11-11 西华大学 Deuterated indoleamine-2,3-dioxygenase inhibitor
PE20180928A1 (en) 2015-07-24 2018-06-08 Newlink Genetics Corp 1-METHYL-D-TRYPTOPHAN SALTS AND PROPHARMACS
WO2017107979A1 (en) 2015-12-24 2017-06-29 Genentech, Inc. Tdo2 inhibitors
CN107056785B (en) * 2016-01-02 2021-06-22 杭州英创医药科技有限公司 Heterocyclic compounds as IDO and TDO inhibitors
AU2017215424A1 (en) 2016-02-02 2018-08-09 Emcure Pharmaceuticals Limited Derivatives of pyrroloimidazole or analogues thereof which are useful for the treatment of inter alia cancer
CN108884104B (en) * 2016-02-19 2021-01-15 正大天晴药业集团股份有限公司 Tricyclic compounds as immunomodulators
CN108884103B (en) * 2016-02-19 2021-01-15 正大天晴药业集团股份有限公司 Tricyclic compounds as immunomodulators
WO2017149469A1 (en) 2016-03-03 2017-09-08 Emcure Pharmaceuticals Limited Heterocyclic compounds useful as ido and/or tdo modulators
CA3021589A1 (en) * 2016-04-29 2017-11-02 Merck Sharp & Dohme Corp. Substituted imidazopyridine compounds as inhibitors of indoleamine2,3-dioxygenase and/or tryptophan-2,3-dioxygenase
WO2017198159A1 (en) * 2016-05-16 2017-11-23 鲁南制药集团股份有限公司 Imidazole derivative containing bridge ring
CN107383012B (en) * 2016-05-16 2021-09-28 鲁南制药集团股份有限公司 Bicyclic imidazole alcohol derivatives
CN107663159A (en) * 2016-07-29 2018-02-06 上海迪诺医药科技有限公司 Polycyclic compound, its pharmaceutical composition and application
JP7358236B2 (en) 2016-09-19 2023-10-10 ユニヴァーシティ オブ サウス フロリダ How to target oncolytic viruses to tumors
TW201815766A (en) 2016-09-22 2018-05-01 美商普雷辛肯公司 Compounds and methods for IDO and TDO modulation, and indications therefor
EP3515914A4 (en) 2016-09-24 2020-04-15 BeiGene, Ltd. NOVEL 5 or 8-SUBSTITUTED IMIDAZO [1, 5-a]PYRIDINES AS SELECTIVE INHIBITORS OF INDOLEAMINE AND/OR TRYPTOPHANE 2, 3-DIOXYGENASES
KR20190084053A (en) 2016-10-13 2019-07-15 주노 쎄러퓨티크스 인코퍼레이티드 Methods and compositions for immune therapy involving tryptophan pathway regulators
WO2018072742A1 (en) * 2016-10-21 2018-04-26 江苏恒瑞医药股份有限公司 Crystalline form of free base of imidazo isoindole derivative and preparation method therefor
EP3560928B1 (en) * 2016-12-20 2021-10-20 Shenzhen Chipscreen Biosciences Co., Ltd. Fused imidazole compound having indoleamine 2,3-dioxygenase inhibitory activity
TWI818902B (en) 2016-12-22 2023-10-21 美商卡利泰拉生物科技公司 Compositions and methods for inhibiting arginase activity
WO2018136437A2 (en) 2017-01-17 2018-07-26 Tesaro, Inc. Compounds useful as inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan dioxygenase
WO2019006047A1 (en) 2017-06-28 2019-01-03 Genentech, Inc. Tdo2 and ido1 inhibitors
WO2019005559A1 (en) 2017-06-28 2019-01-03 Genentech, Inc. Tdo2 and ido1 inhibitors
CN109384791B (en) * 2017-08-09 2020-09-11 江苏恒瑞医药股份有限公司 Crystal form of imidazo isoindole derivative free alkali and preparation method thereof
EP3682900A4 (en) * 2017-09-15 2021-06-16 Taiho Pharmaceutical Co., Ltd. Prophylactic and/or therapeutic agent for diseases involving ido expression
WO2019078246A1 (en) * 2017-10-19 2019-04-25 一般社団法人ファルマバレープロジェクト支援機構 Ido/tdo inhibitor
US11472788B2 (en) 2017-11-25 2022-10-18 Beigene, Ltd. Benzoimidazoles as selective inhibitors of indoleamine 2,3-dioxygenases
WO2019136157A2 (en) 2018-01-05 2019-07-11 Dicerna Pharmaceuticals, Inc. Reducing beta-catenin and ido expression to potentiate immunotherapy
CN112119072A (en) 2018-03-20 2020-12-22 普莱希科公司 Compounds and methods for IDO and TDO modulation, and indications thereof
WO2020018670A1 (en) 2018-07-17 2020-01-23 Board Of Regents, The University Of Texas System Compounds useful as inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan dioxygenase
MX2021003661A (en) 2018-09-28 2021-08-19 Janssen Pharmaceutica Nv Monoacylglycerol lipase modulators.
TW202028198A (en) 2018-09-28 2020-08-01 比利時商健生藥品公司 Monoacylglycerol lipase modulators
CA3156100A1 (en) 2019-09-30 2021-04-08 Janssen Pharmaceutica Nv Radiolabelled mgl pet ligands
KR20220157999A (en) 2020-03-26 2022-11-29 얀센 파마슈티카 엔.브이. monoacylglycerol lipase modulator
US11839659B2 (en) 2020-07-02 2023-12-12 Northwestern University Proteolysis-targeting chimeric molecules (PROTACs) that induce degradation of indoleamine 2,3-dioxygenase (IDO) protein
AU2022228701A1 (en) 2021-03-05 2023-09-14 Universität Basel Compositions for the treatment of ebv associated diseases or conditions
EP4052705A1 (en) 2021-03-05 2022-09-07 Universität Basel Vizerektorat Forschung Compositions for the treatment of ebv associated diseases or conditions

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH516573A (en) * 1967-08-15 1971-12-15 Sandoz Ag Process for the preparation of 5-hydroxy-5-phenyl-2,3-dihydro-5H-imidazo (2,1-a) isoindoles
US5807892A (en) 1994-09-30 1998-09-15 Alcon Laboratories, Inc. Use of certain prostaglandin analogues to treat glaucoma and ocular hypertension
AU1628599A (en) 1997-12-05 1999-06-28 Medical College Of Georgia Research Institute, Inc. Regulation of t cell-mediated immunity by tryptophan
CA2483451C (en) 2002-04-12 2014-07-29 Medical College Of Georgia Research Institute, Inc. Antigen-presenting cell populations and their use as reagents for enhancing or reducing immune tolerance
MY138268A (en) * 2002-05-15 2009-05-29 Janssen Pharmaceutica Nv N-substituted tricyclic 3-aminopyrazoles as inhibitors for the treatment of cell proliferative disorders
EP1613308A4 (en) 2003-03-27 2008-02-20 Lankenau Inst Medical Res Novel methods for the treatment of cancer
DE102007020493A1 (en) 2007-04-30 2008-11-06 Grünenthal GmbH Substituted amide derivatives
JP5583592B2 (en) 2007-11-30 2014-09-03 ニューリンク ジェネティクス コーポレイション IDO inhibitor
WO2009132238A2 (en) 2008-04-24 2009-10-29 Newlink Genetics Ido inhibitors
WO2010056567A1 (en) * 2008-11-13 2010-05-20 Merck Sharp & Dohme Corp. Imidazoisoindole neuropeptide s receptor antagonists
WO2011056652A1 (en) * 2009-10-28 2011-05-12 Newlink Genetics Imidazole derivatives as ido inhibitors
JP2012037986A (en) 2010-08-04 2012-02-23 Canon Inc Image forming apparatus, control method thereof, and image forming system
NO2694640T3 (en) * 2011-04-15 2018-03-17

Also Published As

Publication number Publication date
US9981973B2 (en) 2018-05-29
PE20151593A1 (en) 2015-11-05
JP6093903B2 (en) 2017-03-08
WO2014159248A1 (en) 2014-10-02
US20170260188A1 (en) 2017-09-14
CN105189466A (en) 2015-12-23
CL2015002649A1 (en) 2016-07-29
SG10201707545XA (en) 2017-10-30
KR20150126623A (en) 2015-11-12
JP2016519056A (en) 2016-06-30
MA38493B1 (en) 2017-10-31
US9617272B2 (en) 2017-04-11
AU2017201693A1 (en) 2017-03-30
MX361375B (en) 2018-12-05
RU2015143990A (en) 2017-04-19
IL241027A0 (en) 2015-11-30
MX2015011385A (en) 2016-02-03
EP2976332A1 (en) 2016-01-27
CL2016001940A1 (en) 2017-03-10
JP2017052786A (en) 2017-03-16
AU2014241079C1 (en) 2017-07-06
SA515361127B1 (en) 2017-10-19
UA118103C2 (en) 2018-11-26
AU2014241079A1 (en) 2015-09-03
HK1213259A1 (en) 2016-06-30
AU2014241079B2 (en) 2016-12-15
CR20150485A (en) 2015-11-26
EP3366678A1 (en) 2018-08-29
MA38493A1 (en) 2017-02-28
EP2976332B1 (en) 2018-01-31
RU2667509C2 (en) 2018-09-21
ZA201607948B (en) 2018-05-30
AU2014241079B9 (en) 2017-04-06
JP6352368B2 (en) 2018-07-04
PH12015501866A1 (en) 2015-12-07
US20160060266A1 (en) 2016-03-03
BR112015022588A2 (en) 2017-07-18
CA2902174A1 (en) 2014-10-02

Similar Documents

Publication Publication Date Title
ZA201607948B (en) Tricyclic compounds as inhibitors of immunosuppression mediated by tryptophan metabolization
IL289834A (en) Substituted tricyclic compounds as fgfr inhibitors
HK1225720A1 (en) Spirocyclic compounds as tryptophan hydroxylase inhibitors
AP2016009008A0 (en) Polymorph of syk inhibitors
IL254520A0 (en) Tricyclic heterocyclic compounds useful as inhibitors of tnf
HK1204865A1 (en) Composition for elimination of troublesome varmints